Speaker: Dr. Jeremy Shefner (Barrow Neurological Institute)
An update on the currently enrolling COURAGE-ALS trial will be provided. This will include results of the first interim analysis, a review of the novel mechanism of action for reldesemtiv, and the participant friendly nature of the trial.
